サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566844

トリアムシノロン市場：タイプ別、用途別、流通チャネル別：世界の機会分析と産業予測、2024～2033年

Triamcinolone Market By Type , By Application By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 280 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
トリアムシノロン市場：タイプ別、用途別、流通チャネル別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 280 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

トリアムシノロン市場

トリアムシノロン市場は、2023年に9億米ドルと評価され、2024～2033年にかけてCAGR 3.8%で成長し、2033年には13億米ドルに達すると予測されています。

トリアムシノロンは、抗炎症作用と免疫抑制作用を持つグルココルチコイドで、アレルギー反応、皮膚疾患、関節炎、喘息などの呼吸器疾患など、さまざまな病状の治療に用いられます。この化合物は、身体の特定の部位を対象にしたり、全身的な効果をもたらすために、複数の形態で存在します。これらの形態には、軟膏、外用クリーム、経口錠、注射、点鼻薬などがあります。トリアムシノロンは、ヒスタミンやサイトカインなどの炎症性物質の放出を抑制することにより、腫れ、発赤、かゆみを抑えるのに役立ちます。

慢性疾患の有病率の増加、高齢者人口の急激な増加、医療インフラの拡大がトリアムシノロン市場の主要促進要因です。高齢者は、関節炎、喘息、皮膚疾患などの慢性疾患や炎症性疾患にかかりやすいです。強力なコルチコステロイドであるトリアムシノロンは、効果的な抗炎症と免疫抑制の利点を提供することにより、そのような疾患の症状を顕著に緩和します。ナノ製剤のような高度なドラッグデリバリーシステムによるトリアムシノロンの投与は、呼吸器疾患や慢性皮膚疾患の回復過程を促進するため、治療方法の動向となっています。

しかし、特定の要因がトリアムシノロン市場の開拓を抑制しています。コルチコステロイドであるトリアムシノロンの長期使用や大量投与は、体重増加、皮膚の菲薄化、血糖値の上昇、感染症の高リスクといった深刻な副作用を引き起こします。このため、トリアムシノロンを薬として好まない開業医や患者が多く、市場の成長を抑制しています。それとは反対に、トリアムシノロンはさまざまな健康状態の治療として検討されており、これは将来的な応用可能性が高まっていることを示しています。最新の医療情報を掲載するウェブサイトMedscapeが最近発表した記事によると、トリアムシノロンは甲状腺眼症の治療に優れた薬剤です。トリアムシノロンの経皮的注射は、この疾患におけるマージン反射距離1（MRD1）と上眼瞼後退（UER）の改善に役立ちます。

セグメント別レビュー

トリアムシノロン市場は、タイプ、用途、流通チャネル、地域に区分されます。タイプ別では、市場はクリーム、注射剤、吸入剤に分けられます。用途別では、湿疹、皮膚炎、アレルギー、乾癬、その他に分類されます。流通チャネル別では、ドラッグストア、病院薬局、オンライン薬局に分類されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されます。

主要調査結果

タイプ別では、クリームセグメントが2023年の市場を独占しました。

用途別では、湿疹セグメントが2023年の最高株主でした。

流通チャネル別では、ドラッグストアセグメントが2023年に高いシェアを獲得しました。

地域別では、製薬業界の成長と医療への投資により、アジア太平洋で市場が急速に拡大しています。

本レポートのカスタマイズが可能です（別途費用とスケジュールが必要です。）

  • 規制ガイドライン
  • クライアントの関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • 主要参入企業の詳細（所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 トリアムシノロン市場：タイプ別

  • 市場概要
  • クリーム
  • 注射剤
  • 吸入剤

第5章 トリアムシノロン市場：用途別

  • 市場概要
  • 湿疹
  • 皮膚炎
  • アレルギー
  • 乾癬
  • その他

第6章 トリアムシノロン市場：流通チャネル別

  • 市場概要
  • ドラッグストア
  • 病院薬局
  • オンライン薬局

第7章 トリアムシノロン市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国のトリアムシノロン市場
    • カナダのトリアムシノロン市場
    • メキシコのトリアムシノロン市場
  • 欧州
    • 主要市場動向と機会
    • ドイツのトリアムシノロン市場
    • フランスのトリアムシノロン市場
    • 英国のトリアムシノロン市場
    • イタリアのトリアムシノロン市場
    • スペインのトリアムシノロン市場
    • その他の欧州のトリアムシノロン市場
  • アジア太平洋
    • 主要市場動向と機会
    • 日本のトリアムシノロン市場
    • 中国のトリアムシノロン市場
    • オーストラリアのトリアムシノロン市場
    • インドのトリアムシノロン市場
    • 韓国のトリアムシノロン市場
    • その他のアジア太平洋のトリアムシノロン市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルのトリアムシノロン市場
    • サウジアラビアのトリアムシノロン市場
    • 南アフリカののトリアムシノロン市場
    • その他のラテンアメリカ・中東・アフリカのトリアムシノロン市場

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第9章 企業プロファイル

  • Akorn Inc
  • Bristol Myers Squibb Company
  • Cosette Pharmaceuticals, Inc
  • Glenmark Pharmaceuticals
  • Lupin
  • Mylan N.V.
  • Novartis AG
  • Sun Pharmaceutical Industries Limited
  • Taro Pharmaceutical Industries
  • Teva Pharmaceuticals
目次
Product Code: A66219

Triamcinolone Market

The triamcinolone market was valued at $0.9 billion in 2023 and is projected to reach $1.3 billion by 2033, growing at a CAGR of 3.8% from 2024 to 2033.

Triamcinolone is a glucocorticoid with anti-inflammatory and immunosuppressive properties that is used in the treatment of various medical conditions, including allergic reactions, skin disorders, arthritis, and respiratory illnesses such as asthma. The compound exists in multiple forms to target specific areas of the body or provide systemic effects. These forms include ointments, topical creams, oral tablets, injections, and nasal sprays. Triamcinolone helps to reduce swelling, redness, and itching by inhibiting the release of inflammatory substances such as histamines & cytokines.

Increasing prevalence of chronic diseases, exponentially growing geriatric population, and expansion of healthcare infrastructure are the key drivers of the triamcinolone market. The elderly individuals are highly prone to chronic and inflammatory diseases such as arthritis, asthma, and dermatological conditions. Triamcinolone, being a potent corticosteroid, remarkably alleviates the symptoms of such diseases by providing effective anti-inflammatory and immunosuppressive advantages. The administration of triamcinolone through advanced drug delivery systems such as nano formulations is trending in the treatment procedures as it enhances the recovery process for respiratory and chronic skin conditions.

However, certain factors restrain the development of the triamcinolone market. Being a corticosteroid, prolonged usage or high doses of the compound leads to severe side-effects, including weight gain, skin thinning, increase in blood sugar levels, and high risk of infections. This deters several medical practitioners and patients from preferring triamcinolone as a medication, thereby restraining the market growth. On the contrary, triamcinolone is being explored for the treatment for different health conditions, which indicates its enhanced applicability in the future. According to a recent article published by Medscape, a website publishing latest medical information, triamcinolone is an excellent drug for the treatment of thyroid eye disease. Injection of triamcinolone percutaneously helps to improve margin reflex distance 1 (MRD1) and upper eyelid retraction (UER) in the disease.

Segment Review

The triamcinolone market is segmented into type, application, distribution channel, and region. On the basis of type, the market is divided into cream, injection, and inhalers. By application, it is classified into eczema, dermatitis, allergies, psoriasis, and others. As per distribution channel, it is categorized into drug stores, hospitals pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the cream segment dominated market in 2023.

By application, the eczema segment was the highest shareholder in 2023.

As per distribution channel, the drug store segment acquired high stakes in 2023.

Region wise, the market is rapidly expanding in Asia-Pacific owing to the growing pharmaceutical industry and investments in healthcare.

Competition Analysis

The major players operating in the global triamcinolone market include Akorn Inc, Bristol Myers Squibb Company, Cosette Pharmaceuticals, Inc, Glenmark Pharmaceuticals, Lupin, Mylan N.V., Novartis AG, Sun Pharmaceutical Industries Limited, Taro Pharmaceutical Industries, and Teva Pharmaceuticals. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Cream
  • Injection
  • Inhalers

By Application

  • Eczema
  • Dermatitis
  • Allergies
  • Psoriasis
  • Others

By Distribution Channel

  • Drug Stores
  • Hospitals Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Akorn Inc
    • Bristol Myers Squibb Company
    • Cosette Pharmaceuticals, Inc
    • Glenmark Pharmaceuticals
    • Lupin
    • Mylan N.V.
    • Novartis AG
    • Sun Pharmaceutical Industries Limited
    • Taro Pharmaceutical Industries
    • Teva Pharmaceuticals

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: TRIAMCINOLONE MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Cream
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Injection
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Inhalers
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: TRIAMCINOLONE MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Eczema
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Dermatitis
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Allergies
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Psoriasis
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Others
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country

CHAPTER 6: TRIAMCINOLONE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Distribution Channel
  • 6.2. Drug Stores
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Hospitals Pharmacies
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Online Pharmacies
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: TRIAMCINOLONE MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By Distribution Channel
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Triamcinolone Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By Distribution Channel
    • 7.2.7. Canada Triamcinolone Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By Distribution Channel
    • 7.2.8. Mexico Triamcinolone Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By Distribution Channel
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Triamcinolone Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By Distribution Channel
    • 7.3.7. France Triamcinolone Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By Distribution Channel
    • 7.3.8. UK Triamcinolone Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By Distribution Channel
    • 7.3.9. Italy Triamcinolone Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By Distribution Channel
    • 7.3.10. Spain Triamcinolone Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By Distribution Channel
    • 7.3.11. Rest of Europe Triamcinolone Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By Distribution Channel
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Triamcinolone Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By Distribution Channel
    • 7.4.7. China Triamcinolone Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By Distribution Channel
    • 7.4.8. Australia Triamcinolone Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By Distribution Channel
    • 7.4.9. India Triamcinolone Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By Distribution Channel
    • 7.4.10. South Korea Triamcinolone Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By Distribution Channel
    • 7.4.11. Rest of Asia-Pacific Triamcinolone Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By Distribution Channel
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Triamcinolone Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By Distribution Channel
    • 7.5.7. Saudi Arabia Triamcinolone Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By Distribution Channel
    • 7.5.8. South Africa Triamcinolone Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By Distribution Channel
    • 7.5.9. Rest of LAMEA Triamcinolone Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Akorn Inc
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Bristol Myers Squibb Company
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Cosette Pharmaceuticals, Inc
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Glenmark Pharmaceuticals
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Lupin
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Mylan N.V.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Novartis AG
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Sun Pharmaceutical Industries Limited
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Taro Pharmaceutical Industries
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Teva Pharmaceuticals
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments